- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00948701
Community Volunteers Promoting Physical Activity Among Cancer Survivors (MFT2)
December 3, 2012 updated by: Bernardine M. Pinto, The Miriam Hospital
Physical activity programs, when offered in research settings, have been shown to improve quality of life and reduce fatigue among breast cancer survivors.
The investigators are training Reach to Recovery volunteers at the American Cancer Society (New England Division) to provide a 12-week telephone-based physical activity program (RTR Plus) for breast cancer survivors.
The comparison group of survivors will receive Reach to Recovery services (RTR).
Physical activity, fatigue and other outcomes will be examined among 108 breast cancer survivors at the start of the program, at 12 weeks and 24 weeks.
If the physical activity program is found to be effective, there is a potential for dissemination among the 13,000 Reach to Recovery volunteers across the U.S.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The current study, a randomized controlled trial, represents the next step in our efforts to extend the research on physical activity to the community setting; community volunteers will deliver the intervention, thereby making physical activity interventions much more accessible to survivors.
In partnership with the National ACS office (Atlanta, GA) and the New England ACS Division, researchers at the Miriam Hospital will share their skills, experience and resources to examine the effects of training RTR volunteers to deliver brief physical activity counseling to breast cancer survivors.
Fifteen to twenty RTR volunteers will be trained to offer a 12-week telephone-based PA program as a supplement to 12-week RTR services (RTR Plus) vs. delivering the standard 12-week RTR services (RTR) to 108 breast cancer survivors.
Assessments of physical activity, fatigue and other outcomes will be completed at baseline, 12 weeks and 24 weeks.
Data on side-effects of the intervention and costs of intervention delivery will be tracked.
If the proposed randomized trial demonstrates positive effects, the results will be used to design and support a dissemination trial of the effects of physical activity promotion to enhance cancer recovery in a community setting.
Study Type
Interventional
Enrollment (Anticipated)
108
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Centers for Behavioral and Preventive Medicine, The Miriam Hospital, One Hoppin Street, Suite 314
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion criteria:
Women aged 21 years or over with Stage 0-3 breast cancer will be eligible if they:
- Are requesting Reach to Recovery services from the American Cancer Society.
- Have been diagnosed in the past 5 years with Stage 0-3 breast cancer.
- Are able to read and speak English.
- Are ambulatory.
- Are sedentary (i.e., do not meet recommendations for moderate-intensity PA [30 minutes/ day or more for at least 5 days/ week] or vigorous-intensity PA [20 minutes/day or more for at least 3 days/week].
- Are able to walk unassisted.
- Have access to a telephone.
Exclusion criteria:
Women with:
- More advanced disease (Stage 4).
- Medical or psychiatric problems (e.g., substance abuse, coronary artery disease, peripheral vascular disease, diabetes, and orthopedic problems) that may interfere with protocol adherence will not be included.
- Participants will be asked to provide consent for medical chart review to extract disease and treatment variables. Eligible participants will obtain medical clearance from their physicians.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Phone-based PA program (RTR Plus)
The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials.
RTR volunteers or "coaches" will be asked to contact participants by telephone once a week for 12 weeks.
The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers.
|
RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
Other Names:
|
|
ACTIVE_COMPARATOR: Standard RTR services (RTR)
RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR.
The volunteers will also review the educational materials sent to all participants receiving RTR services.
This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
|
RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Physical activity - recorded via accelerometer and through interviewer-administered Seven Day Activity Recall (7 day PAR).
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fatigue - assessed with FACT-F
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Bernardine M. Pinto, Ph.D., The Miriam Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (ANTICIPATED)
January 1, 2013
Study Completion (ANTICIPATED)
January 1, 2013
Study Registration Dates
First Submitted
July 27, 2009
First Submitted That Met QC Criteria
July 28, 2009
First Posted (ESTIMATE)
July 29, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
December 4, 2012
Last Update Submitted That Met QC Criteria
December 3, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 206208
- 1R01CA132854-01A1 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Moving Forward Together 2
-
Rosalind Franklin University of Medicine and ScienceWithdrawnEmotion Regulation | Activity, MotorUnited States
-
VA Office of Research and DevelopmentCompletedWell-being | Problem-solving | Peer Support | Online Mental Health ProgramUnited States
-
VA Office of Research and DevelopmentCompletedDepression | AnxietyUnited States
-
University of California, San FranciscoNational Institute on Aging (NIA)CompletedDementia | Alzheimer DiseaseUnited States
-
VA Office of Research and DevelopmentRecruitingDepression | Anxiety | Post Traumatic Stress Disorder (PTSD)United States
-
Deirdre DlugonskiRecruiting
-
University of WashingtonNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Enrolling by invitationFetal Alcohol Spectrum Disorders | Prenatal Alcohol ExposureUnited States
-
The University of Texas Health Science Center,...U.S. Army Medical Research and Development Command; Ralph H. Johnson VA Medical...RecruitingMental Disorder | Adjustment DisordersUnited States
-
Medical College of WisconsinNational Cancer Institute (NCI); University of ChicagoCompleted
-
University of RochesterCompletedFetal Alcohol Spectrum DisordersUnited States